Intra Cellular Therapies Top Insiders

ITCIDelisted Stock  USD 131.87  0.03  0.02%   
Intra Cellular employs about 860 people. The company is managed by 16 executives with a total tenure of roughly 52 years, averaging almost 3.0 years of service per executive, having 53.75 employees per reported executive. Assessment of Intra Cellular's management performance can provide insight into the firm performance.
Sharon Mates  Chairman
Co-Founder, Chairman, CEO and Pres
Robert Davis  President
Senior Vice President and Chief Scientific Officer
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

Intra Cellular's latest congressional trading

Congressional trading in companies like Intra Cellular Therapies, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Intra Cellular by those in governmental positions are based on the same information available to the general public.
2025-05-14Representative Josh GottheimerAcquired Under $15KVerify
2025-05-07Representative Gilbert CisnerosAcquired Under $15KVerify
2025-04-11Representative Josh GottheimerAcquired Under $15KVerify
2025-04-08Representative Gilbert CisnerosAcquired Under $15KVerify

Intra Cellular Management Team Effectiveness

The company has return on total asset (ROA) of (0.0696) % which means that it has lost $0.0696 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0858) %, meaning that it created substantial loss on money invested by shareholders. Intra Cellular's management efficiency ratios could be used to measure how well Intra Cellular manages its routine affairs as well as how well it operates its assets and liabilities.

Intra Cellular Workforce Comparison

Intra Cellular Therapies is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 18,127. Intra Cellular holds roughly 860 in number of employees claiming about 5% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.11) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.15) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.15.

Intra Cellular Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Intra Cellular insiders, such as employees or executives, is commonly permitted as long as it does not rely on Intra Cellular's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Intra Cellular insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Intra Cellular Notable Stakeholders

An Intra Cellular stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Intra Cellular often face trade-offs trying to please all of them. Intra Cellular's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Intra Cellular's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Sharon MatesCo-Founder, Chairman, CEO and PresProfile
Robert DavisSenior Vice President and Chief Scientific OfficerProfile
Mark NeumannExecutive Vice President Chief Commercial OfficerProfile
Juan SanchezVice President - Corporate Communications and Investor RelationsProfile
John BardiSenior Vice President - Market Access, Policy and Government AffairsProfile
John CondonGeneral PresidentProfile
Michael OlchaskeySenior Vice President Head of Regulatory AffairsProfile
Sanjeev NarulaExecutive CFOProfile
Lawrence CPACFO, FinanceProfile
Michael JDGeneral VPProfile
CPA CPACFO, FinProfile
Juan MDVice RelationsProfile
Michael PharmDSenior AffairsProfile
Suresh MDExecutive OfficerProfile
Karen EsqSenior OfficerProfile
Willie MDSenior DevelopmentProfile

About Intra Cellular Management Performance

The success or failure of an entity such as Intra Cellular Therapies often depends on how effective the management is. Intra Cellular management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Intra management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Intra management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people.

Intra Cellular Workforce Analysis

Traditionally, organizations such as Intra Cellular use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Intra Cellular within its industry.

Intra Cellular Manpower Efficiency

Return on Intra Cellular Manpower

Revenue Per Employee791.7K
Revenue Per Executive42.6M
Net Loss Per Employee86.8K
Net Loss Per Executive4.7M
Working Capital Per Employee1.3M
Working Capital Per Executive68.9M
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Other Consideration for investing in Intra Stock

If you are still planning to invest in Intra Cellular Therapies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intra Cellular's history and understand the potential risks before investing.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance